News & Documents

Market & Portfolio Commentary - November 2022


November was overall a strong month for financial markets with broad based gains across equities, credit, sovereign bonds and commodities. There were a number of drivers behind this positive momentum. In particular the downside surprises to inflation data in Europe and the US were well received by the market. There are also signs that China is starting to move away from its zero Covid-policy, which is anticipated to boost global growth and ease some of the pressure on supply chains.

European Sub Investment Grade Highlights

The Credit Suisse Western European Leveraged Loan Index return, hedged to Euro, was at +1.92% for the month (-3.61% year to date ("YTD")). Defensives were +1.80% and cyclicals +2.05% in November. CCCs were up +1.45%, single Bs +2.33% and BBs +1.64%. As at the end of November, the 3-year discount margin on the index was 643bps. The Credit Suisse Western European High Yield Index, hedged to Euro, was up +3.33% (YTD -11.35%).a

Primary issuance continues to be slow with €3.0bn term loan ("TL") and €0.7Bn HY Issuance. This includes Nuuday which placed a €500m TL after private syndication, Emeria which priced and upsized a €550m non-fungible loan to fund FirstPort acquisition and Faurecia which completed the issuance of €700m sustainability-linked bonds. Demand was generally strong with both Emeria and Faurecia upsizing deals.b

Portfolio Commentary

November was a very active month on the portfolio management side. We exited/reduced a number of positions, while we added a number of new positions across the performing credit, credit opportunities and CLO books. In the performing credit book, we took profit on a healthcare issuer we had bought only a few months ago. The company paid investors 8 points fee and increased its coupon from 3.5% to 7.5%, and bonds traded up on the back of this. Further in the performing credit book, we added a position in a holiday operator at 96.5, where we anticipate a significant repayment in the next few months on the back of an asset sale.

Within the credit opportunities sleeve, we added to a position in the mid-50s as there was a forced bank seller who wanted to exit its position before year end. The company also reported during the month with strong growth at the top line and EBITDA level, and more importantly very strong order intake. We also added to another position in a UK holiday operator. The company has a March 2024 maturity and is in very advanced negotiations with its revolving credit facility ("RCF") providers to extend the RCF maturity which would be a first step to achieve an all-in refinancing of the remainder of the capital structure. At the purchase price of 88, this results in a c. 20% yield to maturity ("YTM") or an even higher internal rate of return ("IRR") if the outstanding loans get refinanced ahead of maturity. We also initiated a position in a chemicals company with a short dated maturity in the low 90s. Finally, we continue to scale into a building material company whose loans look attractively priced in the low 80s. Even though the near term outlook for the business remains challenging, the pricing already reflects this difficult outlook. This remains an underweight position and we have the ability to increase over time if the price of the loans were to drop further. We financed these positions by reducing some other credit opportunities where earnings have disappointed and the upside is probably longer out than we initially anticipated. Specifically highlighting a provider of medical transportation, where underperformance and weakening liquidity is coinciding with a maturity wall in 2024 causing us to take the decision to exit the name over the short term as we manage risk. Furthermore, we continued to add CLO mezzanine paper, with a focus on BB rated tranches, as this market still hasn't fully recovered from the sell-off we saw in late September/early October on the back of the UK's mini-budget. We added around €9m during the month with discount margins around E+10%.

Across the entire portfolio, as of November month end, the weighted average market price was 83.9, trading at a YTM of 17.2% (€ hedged) / 19.7% (GBP hedged), and delivering a 10.9% (€ hedged) / 13.4% (GBP hedged) running cash yield. This compares to a weighted average price of 96.5 and YTM 8.3% and 7.9% as of December 2021. The increase in yield is due to a) increase in base rates both in EUR and GBP, b) the lower weighted average cash price on the portfolio due to market weakness and c) the attractive new issue spreads we see both in the primary loan and CLO markets. Floating rate instruments comprised 85.0% of the portfolio while 72.6% was invested in senior secured assets. With further rate hikes widely anticipated by the market, there is potential for further upside to these yield numbers. The portfolio had a cash position of 0.8% (including leverage) at the end of the month.

Important disclaimer and terms of use

These written materials are not for release, publication or distribution, directly or indirectly, in or into the United States, Australia, Canada, South Africa or Japan or to "U.S. persons" as defined in Regulation S under the US Securities Act ("US Persons"). The information contained herein does not constitute or form part of any offer or solicitation to purchase or subscribe for securities in the United States, Australia, Canada, South Africa or Japan or any other jurisdiction where to do so might constitute a violation of the relevant laws or regulations of such jurisdiction. The Company has not been and will not be registered under the US Investment Company Act of 1940, as amended (the "Investment Company Act") and, as such, holders of the Company’s securities will not be entitled to the benefits of the Investment Company Act. The securities discussed herein have not been and will not be registered under the US Securities Act of 1933, as amended (the "US Securities Act"), or with any securities regulatory authority of any state or other jurisdiction of the United States and may not be offered or sold in the United States or to, or for the account or benefit of, US Persons absent registration or an exemption from registration under the US Securities Act in a manner that would not require the Company to register under the Investment Company Act. No public offering of securities will be made in the United States. No securities may be offered or sold, directly or indirectly, into the United States or to US Persons absent registration or an exemption from registration under the US Securities Act and in a manner that would not require the Company to register under the Investment Company Act.

In addition, in the United Kingdom, these materials on this website are only being distributed to and are only directed at (i) persons who are outside the United Kingdom or (ii) to investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order") or (iii) high net worth entities, and other persons to whom they may lawfully be communicated, falling within Article 49(2)(a) to (e) of the Order (all such persons in (i), (ii) and (iii) above together being referred to as "relevant persons"). Securities to which the materials relate are only available to, and any invitation, offer or agreement to subscribe, purchase or otherwise acquire such securities will be engaged in only with, relevant persons. Any person who is not a relevant person should not act or rely on the materials or any of their contents.

Any communication on this website is only addressed to and is only directed at persons in any member state of the European Economic Area ("EEA Member State") where any required notification or registration for "marketing" as that term is defined in Article 4(1)(x) of Directive 2011/61/EU on alternative investment fund managers ("AIFMD") has been made and who are both:

  1. "qualified investors" in that Member State within the meaning of Article 2(e) of EU Prospectus Regulation (EU/2017/1129), as amended, including any relevant implementing measure in EEA Member State which has implemented the EU Prospectus Regulation; and
  2. "professional investors" in that EEA Member State within the meaning of Article 4(1)(ag) AIFMD.

A list of EEA Member States in which a notification or registration has been made for marketing to professional investors under AIFMD is available on request.

This website should not be accessed by persons in any EEA Member State who are "retail investors" within the meaning of Article 4(1)(aj) of the AIFMD ("retail investors").

Access to electronic versions of these materials is being made available on the webpage in good faith and for information purposes only. Making press announcements and other documents relating to any offering of securities available in electronic format does not constitute an offer to sell or the solicitation of an offer to buy or subscribe for securities, nor does it constitute a recommendation by any party to sell or buy securities.

By clicking on the "Accept" button, I confirm, represent, warrant and agree that:

I am not a US Person or located in the United States, Australia, Canada, South Africa or Japan or any other jurisdiction where to proceed to view the materials on this webpage would constitute a breach of securities law in that jurisdiction, and I confirm that I am permitted to view electronic versions of these materials; I will not forward, transmit or show the materials contained in this webpage to any US Person or person located in, or a resident of, the United States, Australia, Canada, South Africa or Japan or any other jurisdiction where it would be unlawful to do so; and I have read and understood the disclaimer set out above and will read carefully any additional disclaimers or important notices attaching to or forming part of the materials or information on this website. I understand that this may affect my rights, and I agree to be bound by their terms.

I am not a retail investor located in an EEA Member state.